loading page

Investigating the potential of clinical and biochemical markers to diagnose functional hypothalamic amenorrhoea in females with amenorrhoea: a retrospective observational study.
  • +6
  • Sara Abou Sherif,
  • Rebecca Newman,
  • Sara Haboosh,
  • Ahmed Al-Sharefi ,
  • Nikoleta Papanikolaou,
  • Lisa J Webber,
  • Stephen Franks,
  • Waljit S Dhillo,
  • Channa Jayasena
Sara Abou Sherif
Imperial College London

Corresponding Author:[email protected]

Author Profile
Rebecca Newman
Imperial College London
Author Profile
Sara Haboosh
Imperial College London
Author Profile
Ahmed Al-Sharefi
Imperial College London
Author Profile
Nikoleta Papanikolaou
Imperial College London
Author Profile
Lisa J Webber
Imperial College London
Author Profile
Stephen Franks
Imperial College London
Author Profile
Waljit S Dhillo
Imperial College London
Author Profile
Channa Jayasena
Imperial College London
Author Profile

Abstract

Objective: Functional hypothalamic amenorrhoea (FHA) is a common cause of amenorrhoea, but few non-specialist clinicians are able to diagnose affected women. The aim of this study was to investigate the clinical and biochemical features of FHA, compared to that of polycystic ovarian syndrome (PCOS) and assess the diagnostic performance of the different parameters for differentiating between the two conditions. Design: A retrospective observational study Setting: Specialist reproductive endocrine gynaecology clinic, St Mary’s Hospital, London, UK Population: Women diagnosed with FHA and PCOS following specialist assessment. Methods: Clinical and biochemical data were collected from electronic hospital data base. Results: Compared with PCOS, women with FHA had significantly lower body mass index (BMI) (20.1±2.9 vs 31.1±7.8 kg/m2, P<0.0001) and a thinner endometrium (3.75±2.23 vs 6.82±3.32 mm, P<0.0001). Women with FHA had significantly lower luteinising hormone (LH) (3.46±7.31 vs 8.79±4.98 IU/L, P< 0.0001), as well as lower LH: follicle stimulating hormone (FSH) ratio, estradiol, thyroid-stimulating, free thyroxine and prolactin levels; there was no significant difference in FSH levels. Low BMI had the greatest predictive performance for FHA (area under the curve [AUC]; 0.93, P<0.001), followed by low estradiol (AUC 0.89, P<0.001), low LH (AUC 0.88, P<0.001) and LH:FSH ratio (AUC 0.86, P<0.001). Conclusions: Our data provides quantification for diagnostic accuracy of clinical parameters to differentiate FHA from PCOS, namely low BMI, estradiol, LH and LH:FSH ratio. These data could help clinicians more reliably diagnose FHA in women with secondary amenorrhoea. Key words: Amenorrhoea, Hypogonadism, Polycystic Ovarian Syndrome, Luteinising Hormone